Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060378049> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2060378049 endingPage "10" @default.
- W2060378049 startingPage "2" @default.
- W2060378049 abstract "Apolipoprotein E (ApoE) genotyping was conducted in sporadic Alzheimer’s disease (AD, n = 91) as well as in other dementing disorders including Parkinson’s disease (PD, n = 73), autopsy-confirmed diffuse Lewy body disease (DLBD, n = 16), progressive supranuclear palsy (n = 13), vascular dementia (n = 55), alcoholic dementia (n = 25) and normal control subjects (n = 77). ApoE ε4 allele frequency was significantly higher in AD (33.5%, p < 0.001), DLBD (40.6%, p < 0.001) and demented PD (29.4%, p < 0.05) compared to that in normal controls (11.7%). The association of the ApoE ε4 allele with AD was more pronounced in early-onset AD (46.4%) than in late-onset AD (27.8%). 46% of the AD individuals developed AD without association to ApoE ε4, and ε4 homozygotes were found not only in AD, but also in many of other dementing disorders. These results suggest that ApoE genotyping cannot provide certainty about the presence or absence of AD, and that it should be used as an adjunct to other diagnostic tests for AD. On the other hand, cerebrospinal fluid (CSF) tau levels were significantly elevated (p < 0.0001) in AD (78.0 ± 44.2 pg/ml) compared to those in normal controls (10.6 ± 8.6 pg/ml). The specificity and the sensitivity of distinguishing AD from normal controls was 95.0 and 91.2%, respectively. Elevated CSF-tau levels were also detected in some patients with acute neurological diseases including meningoencephalitis, Creutzfeld-Jacob disease, normal pressure hydrocephalus and vitamin B12 deficiency encephalopathy. Increased CSF-tau levels in AD were found regardless of the age at onset, clinical stage, ApoE genotype, α1-antichymotrypsin genotype, and presenilin-1 genotype. The CSF-tau levels continued to be abnormal during the progression of AD. These results suggest that CSF-tau serves as an unequivocal and reliable biological marker to aid in the clinical diagnosis of AD." @default.
- W2060378049 created "2016-06-24" @default.
- W2060378049 creator A5024057178 @default.
- W2060378049 creator A5042373488 @default.
- W2060378049 creator A5079882790 @default.
- W2060378049 date "1997-01-01" @default.
- W2060378049 modified "2023-10-15" @default.
- W2060378049 title "Apolipoprotein E Genotyping and Cerebrospinal Fluid Tau Protein: Implications for the Clinical Diagnosis of Alzheimer’s Disease" @default.
- W2060378049 doi "https://doi.org/10.1159/000213879" @default.
- W2060378049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9187933" @default.
- W2060378049 hasPublicationYear "1997" @default.
- W2060378049 type Work @default.
- W2060378049 sameAs 2060378049 @default.
- W2060378049 citedByCount "38" @default.
- W2060378049 countsByYear W20603780492012 @default.
- W2060378049 countsByYear W20603780492013 @default.
- W2060378049 countsByYear W20603780492017 @default.
- W2060378049 countsByYear W20603780492018 @default.
- W2060378049 countsByYear W20603780492020 @default.
- W2060378049 countsByYear W20603780492023 @default.
- W2060378049 crossrefType "journal-article" @default.
- W2060378049 hasAuthorship W2060378049A5024057178 @default.
- W2060378049 hasAuthorship W2060378049A5042373488 @default.
- W2060378049 hasAuthorship W2060378049A5079882790 @default.
- W2060378049 hasConcept C126322002 @default.
- W2060378049 hasConcept C134018914 @default.
- W2060378049 hasConcept C142724271 @default.
- W2060378049 hasConcept C2776477761 @default.
- W2060378049 hasConcept C2777427615 @default.
- W2060378049 hasConcept C2779097696 @default.
- W2060378049 hasConcept C2779134260 @default.
- W2060378049 hasConcept C2779281540 @default.
- W2060378049 hasConcept C2779483572 @default.
- W2060378049 hasConcept C2779651940 @default.
- W2060378049 hasConcept C2781389367 @default.
- W2060378049 hasConcept C502032728 @default.
- W2060378049 hasConcept C57089818 @default.
- W2060378049 hasConcept C71924100 @default.
- W2060378049 hasConcept C90924648 @default.
- W2060378049 hasConceptScore W2060378049C126322002 @default.
- W2060378049 hasConceptScore W2060378049C134018914 @default.
- W2060378049 hasConceptScore W2060378049C142724271 @default.
- W2060378049 hasConceptScore W2060378049C2776477761 @default.
- W2060378049 hasConceptScore W2060378049C2777427615 @default.
- W2060378049 hasConceptScore W2060378049C2779097696 @default.
- W2060378049 hasConceptScore W2060378049C2779134260 @default.
- W2060378049 hasConceptScore W2060378049C2779281540 @default.
- W2060378049 hasConceptScore W2060378049C2779483572 @default.
- W2060378049 hasConceptScore W2060378049C2779651940 @default.
- W2060378049 hasConceptScore W2060378049C2781389367 @default.
- W2060378049 hasConceptScore W2060378049C502032728 @default.
- W2060378049 hasConceptScore W2060378049C57089818 @default.
- W2060378049 hasConceptScore W2060378049C71924100 @default.
- W2060378049 hasConceptScore W2060378049C90924648 @default.
- W2060378049 hasIssue "1" @default.
- W2060378049 hasLocation W20603780491 @default.
- W2060378049 hasLocation W20603780492 @default.
- W2060378049 hasOpenAccess W2060378049 @default.
- W2060378049 hasPrimaryLocation W20603780491 @default.
- W2060378049 hasRelatedWork W1943919857 @default.
- W2060378049 hasRelatedWork W197448336 @default.
- W2060378049 hasRelatedWork W1974488420 @default.
- W2060378049 hasRelatedWork W2037167240 @default.
- W2060378049 hasRelatedWork W2052714835 @default.
- W2060378049 hasRelatedWork W2073280832 @default.
- W2060378049 hasRelatedWork W2143894941 @default.
- W2060378049 hasRelatedWork W2414850555 @default.
- W2060378049 hasRelatedWork W2428378021 @default.
- W2060378049 hasRelatedWork W4240116500 @default.
- W2060378049 hasVolume "43" @default.
- W2060378049 isParatext "false" @default.
- W2060378049 isRetracted "false" @default.
- W2060378049 magId "2060378049" @default.
- W2060378049 workType "article" @default.